Mia JD - Karuna Therapeutics General Counsel
Executive
Mia JD is General Counsel of Karuna Therapeutics
| Phone | 857 449 2244 |
| Web | https://www.karunatx.com |
Karuna Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2471) % which means that it has lost $0.2471 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3644) %, meaning that it created substantial loss on money invested by shareholders. Karuna Therapeutics' management efficiency ratios could be used to measure how well Karuna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Karuna Therapeutics currently holds 16.69 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Karuna Therapeutics has a current ratio of 17.41, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Karuna Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 77 | |
| Jeff Lotz | Cytokinetics | N/A | |
| Scott Jordan | Cytokinetics | N/A | |
| Andrew Gengos | Terns Pharmaceuticals | 61 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Diane Weiser | Cytokinetics | N/A | |
| JD Esq | Terns Pharmaceuticals | 56 | |
| John MBA | Dyne Therapeutics | 62 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Eric Terhaerdt | Cytokinetics | N/A | |
| Lucia Celona | Dyne Therapeutics | 59 | |
| MBA MD | Dyne Therapeutics | 58 | |
| YulyMae DiNapoli | Cytokinetics | N/A | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Brett Pletcher | Cytokinetics | 56 | |
| JD Esq | Acumen Pharmaceuticals | 54 | |
| Lauren MBA | Day One Biopharmaceuticals | 49 | |
| Steven JD | Cytokinetics | 66 | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Stuart MD | Cytokinetics | N/A | |
Management Performance
| Return On Equity | -0.36 | |||
| Return On Asset | -0.25 |
Karuna Therapeutics Leadership Team
Elected by the shareholders, the Karuna Therapeutics' board of directors comprises two types of representatives: Karuna Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Karuna. The board's role is to monitor Karuna Therapeutics' management team and ensure that shareholders' interests are well served. Karuna Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Karuna Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alexis Smith, Vice Relations | ||
| Stephen Brannan, Chief Medical Officer | ||
| Andrew Miller, Founder Development | ||
| William Meury, CEO President | ||
| Frank Truslow, Senior Development | ||
| Mia JD, General Counsel | ||
| Ronald MD, Senior Medical | ||
| William Kane, Chief Officer | ||
| Alan Breier, Chair Advisor | ||
| Troy Ignelzi, CFO Sec | ||
| Charmaine Lykins, Chief Officer | ||
| Steven MD, Pres CEO | ||
| Jonathan Rosin, Chief Officer | ||
| Jason Brown, Chief Officer |
Karuna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Karuna Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (755.64) % | |||
| Current Valuation | 11.35 B | |||
| Shares Outstanding | 38.2 M | |||
| Shares Owned By Insiders | 4.98 % | |||
| Shares Owned By Institutions | 86.32 % | |||
| Number Of Shares Shorted | 1.97 M | |||
| Price To Earning | (19.88) X | |||
| Price To Book | 10.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Karuna Stock
If you are still planning to invest in Karuna Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karuna Therapeutics' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |